Amgen Debuts Novel Osteoporosis Therapy Evenity® (Romosozumab) at the 6th China International Import Expo

ShanghaiNovember 8, 2023PR Newswire -- At the 6th China International Import Expo (hereinafter referred to as "CIIE"), Amgen, the global biotechnology leader, appeared again with the theme of "Advancing a Healthier Future," and introduced the innovative osteoporosis treatment Evenity through the "CIIE New Product Launch."^®(Romosozumab)^[1]China's First Exhibition.

Osteoporosis, as the most common skeletal disease affecting residents' health, is a metabolic bone disease characterized by reduced bone mass, destruction of bone microstructure, increased bone fragility, and elevated fracture risk. Evenity^®(Romosozumab) is the world's first approved sclerostin inhibitor jointly developed by Amgen and UCB, featuring a unique dual-action effect that promotes bone formation and inhibits bone resorption, and was ranked as the top medical innovation of 2020 by the Cleveland Clinic.^[2]。

Since 2019, Evenity^®Since its first market launch, Romosozumab has provided innovative treatment options for osteoporosis patients worldwide. Compared with previous anti-osteoporosis drugs, Evenity^®(Romosozumab) works through a novel mechanism of action, slowing bone loss while promoting bone formation, rapidly increasing bone density and reducing fracture risk.

The clinical trial results of PMO show that, compared with placebo, after 12 months of treatment, Evenity^®(Romosozumab) treatment group showed a 12.7% increase in lumbar spine bone mineral density, rapidly reducing the risk of vertebral fractures by up to 73%. Compared with alendronate sodium, after 12 months of treatment, Evenity^®(Romosozumab) significantly reduced new vertebral fractures by 37%.^[3][4]

Currently, according to the latest data, there are approximately 90 million patients with osteoporosis in China, of which about 70 million are women; the prevalence rate among women over 65 years old is as high as 51.6%, while for men it is 10.7%.^[5]Osteoporotic fractures are one of the leading causes of disability and mortality in elderly patients. At the same time, the medical treatment and care for osteoporosis and fractures require a significant investment of human, material, and financial resources, creating a heavy burden on families and society. With the intensification of population aging, osteoporosis is becoming an increasingly serious threat to elderly health.

Since entering the Chinese market in 2012, Amgen has continued to deepen its focus on bone health and actively contribute to healthy aging. Amgen's osteoporosis biologic Prolia has already been launched in China.^®(Prolia, denosumab injection), approved for the treatment of osteoporosis in postmenopausal women at high risk of fractures and men at high risk of fractures.^®It has also won the highest honor in the field of drug research and development, the "Prix Galien Award," which is known as the "Nobel Prize of the pharmaceutical industry." This time, Evenity made its debut in China.^®(Romosozumab) is another commitment by Amgen to provide patients with better innovative treatment options and improve their quality of life. As one of the earliest and largest biotechnology companies globally, Amgen is always dedicated to unlocking the potential of biology to deliver innovative treatments that save lives and improve health. Amgen looks forward to continuing to ride the "CIIE express" to share in the opportunities in China and thereby accelerate the delivery of benefits to more patients.

"Amgen is honored to premiere the innovative osteoporosis treatment Evenity at the CIIE."^®(Romosozumab), sharing Amgen's advanced experience and cutting-edge achievements in biopharmaceuticals, "said Hsu Ai-ling, Vice President of Amgen and General Manager of Amgen China: "The CIIE provides a valuable platform for us to fulfill our mission of serving patients. For Amgen, China is a market of great strategic importance. We focus on four major disease areas, creating a product line that closely aligns with the needs of Chinese patients. We are committed to promoting healthy aging and improving public health, advocating for the establishment of a 'predict and prevent' healthcare ecosystem, and advancing early disease prevention and treatment. We hope to leverage the open platform of the CIIE to introduce more global innovative therapies to China and continuously improve the accessibility of innovative drugs, bringing new hope to more Chinese patients."

[1] Evenity® (romosozumab) has not yet been officially approved for marketing in China.

[2] Cleveland Clinic Unveils Top 10 Medical Innovations for 2020

[3] EVENITY^® (romosozumab-aqqg) prescribing information, Amgen.

[4] Saag KG, Petersen J, Brandi ML, et al. N Engl J Med. 2017;377:1417-1427

[5] Osteoporosis and Bone Mineral Research Branch of Chinese Medical Association, Zhang Zhenlin. Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022) [J]. Chinese General Practice, 2023, 26(14): 1671-1691.